ArticleJournal of virology2025
Syndecan 2 proteoglycan serves as a hepatitis B virus cell attachment receptor.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Promotion of hepatitis B virus infection by extracellular apolipoprotein E.Journal of virology · 2026Article
- T Cell Activation Induces Synthesis of CD47 Proteoglycan Isoforms and Their Release in Extracellular Vesicles.International journal of molecular sciences · 2025Article
- Advances in molecular regulation and function of LDLR family in viral infection.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
We have previously found that human apolipoprotein E (apoE) is enriched on the envelope of infectious hepatitis B virus (HBV) and plays an important role in HBV infection and morphogenesis. Recently, we have demonstrated that the low-density lipoprotein receptor (LDLR) is required for efficient HBV infection. LDLR is a known apoE-binding receptor. Additionally, heparan sulfate proteoglycans (HSPGs) serve as apoE-binding receptors. HSPGs are implicated in HBV infection as HBV cell attachment receptors. HSPGs are composed of heparan sulfate glycosaminoglycans covalently attached to core proteins, including syndecans (SDC1-SDC4) and glypicans (GPC1-GPC6). GPC5 was previously reported as an HBV entry-promoting factor. In the present study, we have identified SDC2 as another cell attachment receptor promoting HBV infection. Small interfering RNA (siRNA)-induced silencing of SDC2 expression resulted in a significant reduction of HBV infection. Likewise, SDC2 gene knockout decreased the susceptibility of hepatocytes to HBV infection. However, the defective HBV infection in the SDC2-deficient hepatocytes could be fully restored by ectopic SDC2 expression. The importance of SDC2 in HBV infection was validated using primary human hepatocytes. Moreover, SDC2 deficiency lowered preS1- and apoE-binding and consequently HBV attachment to the surface of hepatocytes. Collectively, our findings suggest that SDC2 functions as an HBV cell attachment receptor.IMPORTANCEMany different DNA and RNA viruses use HSPGs as cell attachment receptors. HSPGs are composed of core proteins and covalently attached heparan sulfate glycosaminoglycans. Individual SDCs and GPCs play distinct roles in the mediation of cell attachment of different viruses. GPC5 was previously found to promote HBV infection. However, the role of SDCs in HBV infection has not been experimentally examined. In the present study, we have identified SDC2 as an HBV cell attachment receptor. We further found that SDC2-deficient hepatocytes are much less susceptible to preS1- and apoE-binding. These findings suggest that SDC2 promote HBV infection likely through interactions with apoE and preS1, both of which are present on the surface of HBV envelope and contain HSPG-binding sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.